Feb. 04, 2019

Teijin Board Elects Ichiro Watanabe as New President of Teijin Pharma

Teijin Pharma Limited

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, announced today that Teijin’s board of directors has elected Ichiro Watanabe, currently corporate officer of the Teijin Group, as its next president. Watanabe will assume his new role on April 1.
Akihisa Nabeshima, the current president of the company, will assume the post of president, healthcare business of Teijin Group, on the same day.

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the areas of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Its main fields of operation are high-performance fibers such as aramid, carbon fibers & composites, healthcare, films, resin & plastic processing, polyester fibers, products converting and IT. The group has some 170 companies and around 19,000 employees spread out over 20 countries worldwide. It posted consolidated sales of JPY835 billion (USD 7.6 billion) and total assets of JPY 986.2 billion (USD 9 billion) in the fiscal year ending March 31, 2018.
Please visit www.teijin.com

Press Contact

Corporate Communications
Teijin Limited
+81 3 3506 4055